Johnson & Johnson Vision Presents New Myopia, Cataract, Refractive, and Meibomian Gland Dysfunction Data at Virtual ARVO 2021 Annual Meeting

Johnson & Johnson Vision Presents New Myopia, Cataract, Refractive, and Meibomian Gland Dysfunction Data at Virtual ARVO 2021 Annual Meeting
  • Myopia progression data identifies key predictors of teenage High Myopia (HM), which may guide timing of early interventions to reduce risk of HM later in life
  • Higher-order aspheric IOL shown to provide pupil independent performance and better simulated dysphotopsia profile than zonal IOLs in optical bench testing 

JACKSONVILLE, Fla., and SANTA ANA, Cali – May 1, 2021 – Johnson & Johnson Vision*, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies**, will present nearly thirty posters and papers of research data on myopia, intraocular lens (IOL), phacoemulsification, refractive, and meibomian gland dysfunction at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. This year’s premier vision research meeting is being held virtually May 1 – 7, and Johnson & Johnson Vision posters, papers, and presentations can be accessed through the virtual meeting platform hosted by Pathable.

“I’m excited about the data Johnson & Johnson Vision is presenting at ARVO this year,” said Xiao-Yu Song, MD, PhD, Global Head of Research and Development, Johnson & Johnson Vision Care, Inc.*** “We’ve identified markers that can guide clinicians in early interventions for myopia patients and are sharing results from our research that compares the optical and simulated clinical performance of a higher-order aspheric IOL with that of two zonal refractive IOLs.”

Myopia Research Evaluating the Association of Early Childhood Rapid Myopic Progression with High Myopia in Teenagers

Myopia is a chronic and progressive disease that poses the biggest eye health threat of the 21st Century.1 Young children that are less than 12 years of age and become myopic are the most vulnerable to develop high myopia and are at increased risk of sight-threatening eye diseases later in life.2 There is no safe level of myopia.3 From an early age, frequent eye examinations, measuring and monitoring both refractive error and axial length is highly recommended in all children with even moderate risk of myopia progression. 

At ARVO 2021, Johnson & Johnson Vision will present research aiming to better understand how myopia progresses and how it might be intercepted by investigating underlying mechanisms. The results from this and other studies stem from the company’s comprehensive myopia clinical research program, as well as from the research collaboration with the Singapore Eye Research Institute (SERI): 

  • Rapid Myopic Progression in Early Childhood is Associated with Teenage High Myopia. Lanca, Carla et al. This study evaluated the association of early childhood progression of spherical equivalent (SE) and axial length (AL), with high myopia (HM) in teenagers in the Singapore Cohort study Of the Risk factors for Myopia (SCORM). Children (n=1,051) were followed from baseline (6-11 years-old) over a mean follow-up of 6.9±1.0 years. Regression analyses showed myopia progression in early childhood combined with other key factors, such as baseline SE or AL or age of onset of myopia, was a good predictor of teenage HM. The authors suggest clinicians use these factors to guide timing of early interventions to potentially reduce the risk of HM later in life. 

The Optical and Simulated Clinical Performance of Higher-Order Aspheric IOL and Standard Zonal IOLs

More than 90% of people develop cataracts—the clouding and yellowing of the lens in the eye—by the age of 65.4 While part of the normal aging of the eye, left untreated, cataracts cause vision to deteriorate over time. Cataract surgery is one of the most common outpatient procedures performed and has a success rate of approximately 98%.5 During the surgery, an IOL is implanted to replace the eye's natural lens, helping restore vision after a cataract has been removed. 

The poster being presented at ARVO 2021 compares the simulated optical performance of a higher-order aspheric IOL with that of two zonal refractive IOLs with a central add power:

  • Optical performance of different refractive technologies that increase the depth of focus. Alarcon A, et al. This study was designed to compare the optical and predicted clinical performance of a higher-order aspheric IOL with two zonal refractive IOLs with a central add power using optical bench testing measurements and computer simulations. Binocular visual acuity was simulated and calculated from measurements collected in an average corneal eye (ACE) model, and computer simulations in a physiological eye were performed to determine the halo profile for different pupil sizes. The results show that the addition of an add power results in a strong pupil dependence and an optical performance that resembles a standard multifocal IOL, with bifocal defocus curves, loss in distance image quality and the perception of halos.  In comparison, the higher-order aspheric IOL creates a continuous change in power to extend the depth of focus, providing a pupil independent performance, and better simulated dysphotopsia profile than the zonal IOLs.

Additional posters and papers from Johnson & Johnson Vision and its research partners at the ARVO Annual Meeting 2021 include:


  • Short-term axial length changes and visual effects from exposure to a high plus concentric ring optical design. Yi, Fan
  • High myopia prevalence as a function of myopia prevalence and age. Brennan, Noel
  • The Underestimated Role of Myopia in Projected Visual Impairment in the United State. Bullimore, Mark 
  • ‘Physiologic’ Eye Growth in Myopic Children, Nixon, Alex
  • The impact on eye length and vision performance for a range of positive defocus levels in two-zone bifocal contact lens adaptive optics simulations, Davis, Brett
  • The impact on short term axial length and vision performance of myopia control optics with coaxial and non-coaxial plus power lenslets. Yi, Fan
  • Decreased Macular Sensitivity in Highly Myopic Eyes with Myopic Macular Degeneration is Associated with Reduced Outer Retinal Perfusion Density^. Zheng, Feihui

Cataract, Refractive, and Meibomian Gland Dysfunction: 

  • Impact of glare strength on Contrast Sensitivity. Ribeiro, Faria
  • Comparison of objective and subjective light scatter originating from intraocular lenses. Van der Mooren, Marie
  • Light intensity distribution of presbyopia-correcting intraocular lenses. Weeber, Henk
  • Small-bore, dual-durometer aspiration tubing mitigates post-occlusion surge and improves chamber stability.  Zhou, Jianbo
  • Full field tissue profilometry with at least 300nm precision is demonstrated on cornea. Vankov
  • Refraction vs. Keratometry Comparisons After Wavefront-Guided LASIK and Wavefront-Guided Photorefractive Keratectomy. Wang, Y
  • Development of a meibomian gland dysfunction model. Gallois-Bernos, Annabelle

About Johnson & Johnson Vision*
At Johnson & Johnson Vision*, part of Johnson & Johnson Medical Devices Companies, we have a bold ambition: to change the trajectory of eye health worldwide. Through our operating companies, we deliver innovation that enables eye care professionals to create better outcomes for patients throughout their lives, with products and technologies that address unmet needs including refractive error, cataracts, and dry eye. In communities with greatest need, we work in collaboration to expand access to quality eye care, and we are committed to helping people see better, connect better, live better. Visit us at, follow @JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook

About Johnson & Johnson Medical Devices Companies**
At Johnson & Johnson Medical Devices Companies, we are helping people live their best lives. Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people’s healthcare experiences. In surgery, orthopaedics, vision, and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere.

Risk Information

While complications are rare, there are risks to routine cataract surgery.  This is irrelevant to the lens you choose. The problems could be minor, temporary, or affect your vision permanently. These may include worsening of your vision, bleeding, or infection. Pre-existing diseases or conditions (e.g., diabetes, heart disease, and previous eye trauma) may place you at higher risk of experiencing complications and/or more difficult recovery after routine cataract surgery. With some lenses, you may experience some loss in the sharpness of your vision, even with glasses. A small number of patients may want to have their IOL removed. This can be due to lens-related optical/visual symptoms. You should discuss all risks and benefits with your eye doctor before surgery.

©Johnson & Johnson Vision Care Inc., 2021. All rights reserved.

*Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.
**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopedics, vision, and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment

1 JJV data on file - Myopia Compendium.
2 Hu et al “Association of Age at Myopia Onset With Risk of High Myopia in Adulthood in a 12-Year Follow-up of a Chinese Cohort" Jama Oph 2020).
3 Flitcroft. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res. 2012;31:622.
4 Kellogg Eye Center. Cataract.
5 Vision Health Initiative, Common Eye Disorders. Centers for Disease Control and Prevention.
† The TECNIS EyhanceTM IOLs are designed to slightly extend the depth of focus compared to the TECNIS® 1-Piece IOL, Model ZCB00 as measured in bench testing.
^ Study stems from the SERI and Johnson & Johnson Vision myopia research collaboration